Insmed reports first quarter 2023 financial results and provides business update

—enrollment complete in phase 3 aspen trial of brensocatib in adult patients with bronchiectasis; topline data readout on track for second quarter of 2024— —company to provide detailed update on early-stage research programs on may 8, 2023— —company on track to share topline data from post-marketing arise study of arikayce® (amikacin liposome inhalation suspension) in third quarter of 2023— —arikayce total revenue of $65.2 million for the first quarter of 2023, reflecting 23% annual growth over the first quarter of 2022— —company reaffirms full-year 2023 guidance for global arikayce revenues of between $285 million and $300 million— bridgewater, n.j. , may 4, 2023 /prnewswire/ -- insmed incorporated (nasdaq: insm), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported financial results for the first quarter ended march 31, 2023 and provided a business update.
INSM Ratings Summary
INSM Quant Ranking